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Abstract 
 
Cytochrome P450s are natural catalysts capable of performing many chemically challenging reactions 
under mild conditions with high regio- and stereo-selectivity. Biotransformations of various 
biotechnologically and pharmaceutically important compounds with two P450s from Bacillus 
megaterium, CYP106A2 and CYP109E1, were studied within this work. The investigated compounds 
include steroidal drugs, sterols, statins, flavorings and odorants. The reactions were characterized 
through binding titrations, in vitro conversions using the bovine adrenal redox chain, and whole-cell 
biotransformations with P450-based systems in B. megaterium. The results showed the 15β 
hydroxylase activity of CYP106A2 towards glucocorticoid drugs, prednisone and dexamethasone. 
Applying different CYP106A2-based whole-cell systems, the production of the 15β-hydroxylated 
drugs and new drug derivatives was demonstrated. Furthermore, the substrate range of CYP109E1 
was expanded with 13 compounds. Selective transformations of new substrates were accomplished by 
CYP109E1 in vitro as well as in vivo and biotechnologically attractive reactions were identified. 
Among them, the conversion of compactin to pravastatin was further investigated with CYP109E1 
mutants, identifying a variant with 2.5 times greater productivity. Furthermore, CYP109E1 was 
shown to produce valuable oxysterols and a whole-cell biocatalyst was established in E. coli showing 
3.3-fold higher activity than the B. megaterium system.  
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Zusammenfassung 
 
Cytochrome P450 sind natürlich vorkommende Biokatalysatoren, die eine Vielzahl chemisch 
anspruchsvoller Reaktionen unter milden Bedingungen mit einer hohen Regio- und Stereoselektivität 
durchführen. Die Biotransformation von biotechnologisch and pharmazeutisch wichtigen 
Verbindungen (steroidale Medikamente, Sterole, Statine, Aroma- und Geruchsstoffe) wurde  mit den 
Enzymen CYP106A2 und CYP109E1 aus Bacillus megaterium untersucht. Die Charakterisierung 
dieser Reaktionen erfolgte mittels Bindungsstudien, in vitro Umsätzen unter Verwendung der bovinen 
adrenalen Redox-Kette und Ganzzell-Biokatalyse in B. megaterium. CYP106A2 zeigte eine 15β-
Hydroxylase-Aktivität gegenüber den Glucocorticoid Arzneimitteln, Prednison und Dexamethason. 
Unter Einsatz verschiedener B. megaterium Stämme konnte die Produktion von 15β-hydroxy-
Steroiden sowie neuer Arzneimittelderivate erreicht werden. Des Weiteren wurde das 
Substratspektrum von CYP109E1 um 13 Verbindungen erweitert. Durch die selektiven in vitro und in 
vivo Umsätze dieser neuen Substrate mittels CYP109E1 konnten biotechnologisch interessante 
Reaktionen gefunden werden. Der Umsatz von Compactin zu Pravastatin wurde dabei näher 
untersucht, wobei eine CYP109E1 Mutante eine 2,5-fach höhere Produktivität zeigte. Zudem konnte 
CYP109E1 zur Produktion wertvoller Oxysterole eingesetzt werden. Mit Hilfe eines neuen Ganzzell-
Systems in E. coli konnte deren Ausbeute im Vergleich zu dem B. megaterium System um das 3,3-
fache gesteigert werden. 
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1. Introduction 
1.1 Cytochrome P450 monooxygenases 
 
Cytochrome P450s (P450s) are important heme-containing proteins that are ubiquitously distributed 
in nature. They build one of the most diverse and largest superfamily of metalloenzymes and are 
involved in many metabolic and synthetic processes (Sligar, 1999). For example, in mammals P450s 
synthesize steroid hormones, fat-soluble vitamins, bile acids and metabolize drugs as well as 
xenobiotics (Bernhardt, 2006). In plants they contribute in the pathways of secondary metabolism: in 
coloration, in lignification, in the synthesis of defense chemicals, and in degradation of herbicides 
(Guengerich, 2001; Werck-Reichhart and Feyereisen, 2000). In microbes P450s are involved in the 
synthesis of bioactive compounds as well as in the degradation and utilization of animal and plant 
metabolites (Kelly and Kelly, 2013; Müller et al., 1984). 
The research on P450s started 60 years ago when Klingenberg and Garfinkel independently reported 
about a presence of unknown pigments in rat and pig liver microsomes having an intense absorption 
band at 450 nm in the reduced carbon monoxide bound complex (Garfinkel, 1958; Klingenberg, 
1958). Few years later, this unique spectral property gave the name ''P450'' (meaning “Pigment 450”) 
to these heme enzymes (cytochromes) (Omura and Sato, 1962, 1964). Very soon thereafter these 
special proteins have been found in other tissues, organs and organisms (Cardini and Jurtshuk, 1968; 
Estabrook et al., 1963; Katagiri et al., 1968; Lebeault et al., 1971; Ruhmann-Wennhold et al., 1970), 
and nowadays, there are already over 41000 identified genes from hundreds of species in the P450 
database (Nelson, 2018). 
1.1.1 Nomenclature and reaction types 
 
The rapidly increasing number of identified P450s lead to inconsistent naming by different working 
groups such as “P-450BM-3”, “P-450CAM” or  “P450SCC”/“20,22 desmolase”, showing the necessity of a 
universal nomenclature already in the 1980s. Consequently, a standardized P450 nomenclature based 
on the similarity of amino acid sequences was introduced and (slightly modified) is still being used 
(Nebert et al., 1987). The enzymes with more than 40% sequence identity are grouped in the same 
family expressed with a number, whereas the ones with more than 55% similarity belong to the same 
subfamily indicated by a letter of the alphabet. A digit after the subfamily letter is given to enzymes 
consecutively. For example, CYP109E1 is the first P450 enzyme from the 109th family and E 
subfamily (Figure 1).  
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Figure 1. Systematic nomenclature of P450s on the example of CYP109E1 
P450s belong to a large subclass of enzymes called external monooxygenases also known as mixed-
function oxidases (oxygenase and oxidase). Thus, they catalyze the scission of atmospheric dioxygen 
and the insertion of one oxygen atom into organic molecules as well as the reduction of the second 
oxygen atom to water. For the catalysis, they require two electrons from an external donor which in 
most cases is NAD(P)H (Figure 2) (Bernhardt, 2006; Fasan, 2012; Hannemann et al., 2007). 
 
Figure 2. General reaction catalyzed by P450s 
Hydrocarbon hydroxylation is the most common reaction catalyzed by P450 enzymes. Further 
reaction types occurring through P450-mediated catalysis include epoxidation, N-hydroxylation, N-, 
O-, S-dealkylation, C–C bond cleavage, aromatization, lactonization, oxidative deamination, oxidative 
phenol coupling and others (Sono et al., 1996). Table 1 provides several P450-catalyzed reaction 
types with selected examples such as aliphatic hydroxylation of vitamin D3 into 25-hydroxyvitamin 
D3, testosterone ring aromatization forming estradiol, cholesterol side chain cleavage forming the 
general steroid hormone precursor pregnenolone, and 14α-demethylation of lanosterol leading to 
sterol synthesis (by mammalian CYP27A1, CYP19A1, CYP11A1 and CYP51A1, respectively). The 
aromatic ring epoxidation example shows a "bad behavior" of hepatic microsomal CYP1A1 
contributing to the metabolic activation of the carcinogen benzo(a)pyrene. Other examples such as 
oxidation of castasterone to plant hormone brassinolide (a Baeyer-Villiger oxidation) by plant 
CYP85A2, epoxidation of epothilone D to the anticancer agent epothilone B by bacterial CYP167A1 
and degradation of harmful naphthalene (aromatic ring hydroxylation), a "good behavior" of bacterial 
CYP101A1, are also listed. Although showing a tiny fraction of P450-catalyzing biotransformations, 
the examples from Table 1 emphasize the importance and versatility of these enzymes in nature. 
Based on their metabolic functions the numerous members of P450 superfamily can be divided into 
P450s involved in catabolic processes and P450s contributing to anabolic reactions. Both groups are 
highly important for medicine, health, environment and industry. 
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Table 1. P450-catalyzed reaction types and some important examples 
Reaction type Example  P450 Reference 
Aliphatic 
hydroxylation 
vitamin D3 -> 25-hydroxyvitamin D3 CYP27A1 (Cali and Russell, 
1991) 
Aromatic 
hydroxylation 
naphthalene ->1- naphthol CYP101A1 (England et al., 1998) 
Epoxidation epothilone D -> epothilone B CYP167A1 (Ogura et al., 2004) 
Aromatic 
epoxidation 
benzo(a)pyrene -> benzo(a)pyrene-7,8-
epoxide 
CYP1A1 (Moorthy et al., 2015) 
Aromatization testosterone -> estradiol CYP19A1 (Kellis and Vickery, 
1987) 
Demethylation lanosterol -> sterols CYP51A1 (Lepesheva and 
Waterman, 2004) 
C-C bond 
cleavage 
cholesterol -> pregnenolone CYP11A1 (Matteson et al., 1984) 
Baeyer-Villiger 
oxidation      
castasterone -> brassinolide CYP85A2 (Kim et al., 2005) 
 
1.1.2 Electron transfer and catalytic cycle 
 
The vast majority of P450s is not able to obtain necessary electrons from NAD(P)H directly (Ewen et 
al., 2012). For this, they require electron-transporting proteins, called redox partners. P450 enzyme 
systems are classified according to the composition of these proteins (Hannemann et al., 2007). The 
majority of prokaryotic and eukaryotic mitochondrial P450s belong the class I. They occur as three-
component systems consisting of a P450, a FAD-containing reductase (FdR), and a ferredoxin (Fdx) 
of different cluster types among which [2Fe-2S] is most common (Matsubara and Saeki, 1992). In 
class I systems of prokaryotes the proteins are exclusively cytosolic and soluble (Figure 3a), whereas 
in systems of eukaryotes only Fdx is a soluble protein of the mitochondrial matrix (Figure 3b). The 
two other components of mitochondrial systems, P450 and FdR, are bound and associated to the inner 
mitochondrial membrane, respectively (Hannemann et al., 2007). In these systems, the soluble Fdx is 
proposed as an electron “shuttle” between FdR and P450s and has been shown to be required in 
excess over FdR for sufficient activity of CYP11A1 and CYP11B1, two important mitochondrial 
class I systems (Bernhardt, 2006; Lambeth et al., 1979).       
Most of the eukaryotic P450s belong to microsomal class II systems. These two-component systems 
comprise proteins integrated in the endoplasmic reticulum (ER) membrane: P450 and cytochrome 
P450 reductase (CPR) (Figure 3c). The correct orientation of these two proteins in the membrane is a 
necessary prerequisite for the catalytic activity and is controlled by the orientational matrix of 
phospholipids (Ruckpaul and Bernhardt, 1984). Besides the common class II systems, other systems 
from the same class are also reported, in which cytochrome b5 alone or together with cytochrome b5 
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reductase provides the second electron (Correia and Mannering, 1973; Hannemann et al., 2007). Apart 
from being an electron transporter, cytochrome b5 can act as an effector on hepatic P450 (Hlavica, 
1984). In addition to the most abundant class I and class II systems, other one-, two- and multi-
component systems have also been reported (classes III-X), for example, the self-sufficient 
CYP102A1 from Bacillus megaterium (B. megaterium) (naturally fused with its redox partner) and 
CYP176A1 from Citrobacter braakii having flavodoxin instead of ferredoxin as a component of its 
P450 system (Hannemann et al., 2007; Hawkes et al., 2002; Narhi and Fulco, 1987).        
 
Figure 3. Class I bacterial (a) and mitochondrial (b) as well as class II microsomal (c) systems. Figure adapted 
from Hannemann et al. (2007) 
As mentioned before, P450s need two electrons derived from NAD(P)H via redox partner(s) to react 
with atmospheric dioxygen and to insert one oxygen atom into a substrate. Direct reactivity of 
dioxygen (triplet) with stabile organic molecules (singlets) at ambient temperatures is a spin-
forbidden process in chemistry (Sono et al., 1996). P450 enzymes utilize heme-ligated iron for the 
activation of molecular oxygen and perform a multistep catalytic cycle leading to an oxygenated 
product (Figure 4). The resting enzyme is in the ferric state (1) and usually has a water molecule as 
sixth axial ligand (Sligar, 1999). Substrate binding displaces the water (2) and changes the heme iron 
spin state and redox potential. The redox potential of the heme increases to a value higher than that of 
the redox protein, and this difference thermodynamically enables the first electron transfer (Ortiz de 
Montellano, 2010; Sligar, 1999). The enzyme is in the ferrous state (3) after electron transfer and goes 
in the ferric superoxy state (4) after dioxygen binding. This is followed by a second electron transfer, 
yielding the ferric peroxy anion (5), which is subsequently protonated, resulting in the ferric 
hydroperoxy state called compound 0 (Cpd 0) (6). This intermediate is not stabile and is further 
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protonated resulting in the highly reactive ferryl intermediate called compound I (Cpd I) (7), which 
initiates hydrogen abstraction from a C-H bond resulting in formation of the compound II (Cpd II) (8). 
This metal bound hydroxide rapidly "rebounds" to the substrate radical, forms oxygenated product (9) 
and returns the enzyme in the ferric state (1) (Groves et al., 1978; Huang and Groves, 2017; Rittle and 
Green, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Scheme of the catalytic cycle of P450s. Figure adapted from Yashimoto and Auchus (2016) and 
Denisov et al. (2005)  
It is noteworthy that in many P450s at least three unproductive pathways, called “shunt” reactions, 
can occur at different steps of the catalytic cycle: autooxidation shunt, peroxide shunt and oxidase 
shunt (Denisov et al., 2005). In these cases, a P450 consumes electrons and from the ferric superoxy 
(4), the ferric hydroperoxy (6), or the ferryl (7) state returns to the ferric resting state (2) without 
forming the oxygenated product. As a consequence, the bound oxygen is released as superoxide anion 
(O2
-
) after the first electron transfer, as hydrogen peroxide (H2O2) after two-electron reduction, or as 
water after four-electron reduction (Figure 4) (Denisov and Sligar, 2015). On the other hand, a 
number of P450s such as CYP152A1 from Bacillus subtilis (B. subtilis) and CYP191A1 from 
Mycobacterium smegmatis are able to directly use peroxides for substrate oxidation without the need 
for NAD(P)H regeneration, redox partners, or molecular oxygen activation via the catalytic cycle 
(Bernhardt, 2006; Jo et al., 2017; Matsunaga et al., 2002; Sakaki, 2012). 
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1.1.3 Structure and spectroscopic features 
 
Despite the functional diversity and low sequence identity (in some cases <15%), all P450s possess a 
quite conservative unique protein fold and have one invariant amino acid, cysteine, as the fifth or 
proximal ligand of the heme prosthetic group (Munro et al., 2002; Peterson and Graham, 1998). The 
structural core of these proteins is conserved, whereas the regions responsible for substrate 
recognition and binding as well as redox partner binding are variable. The P450 core consists of 
helices D, E, J, L, I, K, two sets of β sheets and a coil structure called "meander" (Figure 5a) (Peterson 
and Graham, 1998; Werck-Reichhart and Feyereisen, 2000). The I helix contains a highly conserved 
threonine with an acidic residue, whereas the K helix includes a fully conserved E-X-X-R motif. 
Furthermore, there is a characteristic sequence F-X-X-G-X-R-X-C-X-G with the absolutely conserved 
cysteine residue on the proximal face of the heme just prior to the L helix (Werck-Reichhart and 
Feyereisen, 2000).  
 
 
 
 
 
 
 
 
 
Figure 5. Secondary and tertiary structures of P450s. Topology diagram of the secondary structural elements on 
the example of CYP102A1 (a). Figure adapted from Werck-Reichhart and Feyereisen (2000). Tertiary structure 
model of P450s with six SRSs on the example of CYP102A1 (b). Figure adapted from Urlacher and Eiben 
(2006). Tertiary structure model of CYP109E1 (c). The model was generated using PyMOL (DeLano Scientific, 
CA, USA) and substrate-free crystal structure of CYP109E1 (PDB ID: 5L90) (Jóźwik et al., 2016)  
The conserved rigid architecture of P450s near the heme is essential to provide a suitable electrostatic 
environment around the cysteine-iron ligation for the maintenance of the redox potential in a 
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physiologically reasonable range (Poulos and Johnson, 2015). In addition, the highly conserved part 
of the I helix near the heme is thought to be involved in specific positioning and stabilization of 
waters, which is crucial for proper proton delivery and oxygen activation (Denisov and Sligar, 2015). 
As it was already mentioned, the regions related to the substrate specificity are not consistent and it is 
not surprising that they vary the most. For example, the B′ helix can occur in orientations differing by 
90° (Poulos and Johnson, 2015). There are six known regions in the P450 structure related to substrate 
recognition (SRSs) identified by Gotoh for CYP101A1 and its natural substrate camphor (Figure 5b): 
SRS1 (BC loop and B′ helix), SRS2 (part of the F helix), SRS3 (part of the G helix), SRS4 (part of the 
I helix), SRS5 (the K helix with β2 region) and SRS6 (β4 hairpin structure) (Gotoh, 1992). Due to the 
characteristic fold of these enzymes (Figure 5b and c), the equivalent structural regions in different 
P450s are considered to be SRSs.    
It is important to note that the heme of P450s, a non-covalently bound iron protoporporphyrin IX, is 
very sensitive to changes in its ligands as well as in its redox state and enables spectroscopic 
monitoring of chemical transformations and transitions (Urlacher and Eiben, 2006; Yoshimoto and 
Auchus, 2016). The UV/Vis spectrum of the heme prosthetic group in the low-spin state shows a red-
shifted Soret band at approximately 380–420 nm as well as two other minor characteristic α (560 nm) 
and β (525 nm) peaks (Bernhardt, 2006; Ruckpaul and Bernhardt, 1984). Binding of carbon monoxide 
to the reduced P450 shifts the Soret band to 450 nm, which is a characteristic feature of an active 
P450 and is used to determine the concentration of a purified enzyme (Omura and Sato, 1964). The 
binding of a cognate substrate to the active site increases the redox potential and changes the spin 
state from low-spin (S=1/2) to high-spin (S=5/2) ferric state (Denisov et al., 2005). The spin state 
transition upon substrate binding shifts the Soret band from about 420 nm to approximately 390 nm 
(type I difference spectrum), whereas an inhibitor binding shifts the maximum to approximately 425 
nm (type II difference spectrum) (Jefcoate, 1978). Optical difference spectroscopy is a powerful 
technique for binding titrations in order to identify dissociation constants of P450 ligands and can be 
also used for high-throughput screening (HTS) of potential P450 substrates (Khatri et al., 2016; 
Schmitz et al., 2012). 
1.1.4 Substrate diversity 
P450 substrates comprise a plethora of hydrophobic chemical structures with diverse functionalities 
such as physiological substances, synthetic pharmaceuticals, aroma compounds and environmental 
pollutants. According to the physiological role of particular P450s, some of them have a very strict 
substrate and reaction spectrum, while the others have broader catalytic activity and selectivity. For 
example, human 25-hydroxyvitamin D3 1α-hydroxylase, CYP27B1, shows high substrate specificity, 
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converting exclusively terminally hydroxylated vitamin D3 derivatives (Tang et al., 2013), whereas 
human hepatic CYP3A4 possesses the longest list of substrates, metabolizing approximately 50% of 
existing drugs (Guengerich, 1999).  
Steroids and steroid alcohols, such as cholesterol, are important substrates of different P450s. In 
mammals, several P450s are involved in multistep pathways of steroidogenesis (producing 
glucocorticoids, mineralocorticoids and sex hormones): mitochondrial CYP11A1 (cholesterol side-
chain cleavage), CYP11B1 (steroid 11β-hydroxylase), CYP11B2 (aldosterone synthase), as well as 
microsomal CYP17A1 (steroid 17α-hydroxylase/17,20-lyase), CYP19A1 (aromatase), and CYP21A2 
(steroid 21-hydroxylase) (Bureik and Bernhardt, 2007). There are three other P450s acting directly on 
cholesterol: microsomal CYP46A1 (24(S)-hydroxylase), CYP7A1 (7α-hydroxylase), and 
mitochondrial CYP27A1 (27-hydroxylase) (Pikuleva, 2006). Several P450s contribute to the 
activation and deactivation of an essential seco-steroid, vitamin D, such as mitochondrial CYP27A1 
(25-hydroxylase of vitamin D), CYP27B1 (1α-hydroxylase of 25-hydroxy vitamin D), CYP24A1 (24-
hydroxylase of 25-hydroxy vitamin D and 1α,25-dihydroxy vitamin D), and microsomal CYP2R1 
(25-hydroxylase of vitamin D) (Schuster, 2011). Various microbial P450s also accept steroids as their 
substrates and perform selective hydroxylations at different sites of steroid (gonane) nucleus. Some of 
them are capable of a terminal oxidation of the side chain (Bureik and Bernhardt, 2007; Donova and 
Egorova, 2012; Sakaki et al., 2011). Besides the physiological steroidal compounds, bacterial P450s 
can also metabolize synthetic steroids, such as the glucocorticoid drugs prednisone and 
dexamethasone. 
Plant and fungal natural products are common P450 substrates. It is not surprising since numerous 
P450s are involved in biosynthetic pathways. One of the important examples is plant CYP71AV1 
from Artemisia annua, which is able to hydroxylate the sesquiterpene amorpha-4,11-diene to the 
antimalarial drug precursor artemisic acid (Teoh et al., 2006). Several plant P450s contribute to the 
synthesis of a phytochemical anticancer drug, a taxol diterpenoid, paclitaxel, such as CYP725A4 
capable of 5α-hydroxylation of an intermediate, taxa-4(5),11(12)-diene (Hefner et al., 1996). 
Flavonoids, plant polyphenols with mainly antioxidant properties, represent an interesting class of 
P450 substrates and ligands. Besides the plant P450s, which transform various flavonoids in their 
biosynthetic pathways (producing defence compounds, pigments and odors), there are other P450s, 
especially in mammals, interacting with these compounds (Hodek et al., 2002). Some flavonoids are 
substrates of mammalian enzymes, whereas others show therapeutically highly important stimulatory 
or inhibitory effects on xenobiotic-metabolizing P450s: CYP1A1, CYP1A2, CYP2B1 and CYP3A4 
as well as steroidogenic CYP19A1 (aromatase) (He et al., 1998; Hodek et al., 2002; Lu et al., 2012; 
Zhai et al., 1998). Similar to plants, numerous fungal primary and secondary metabolites are 
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characterized as P450 substrates (Durairaj et al., 2016). One of the important examples is lovastatin, a 
powerful statin drug, which is a natural product of Aspergillus terreus and is metabolized by hepatic 
CYP3A4 (Barriuso et al., 2011). Other significant P450 substrates include diverse drugs, fatty acids, 
alkanes and polycyclic aromatic hydrocarbons (PAHs).  
In general, the number of P450s with known physiological function is much lower than that with 
unknown natural role, including eight orphan P450 enzymes encoded by the human genome (Nebert 
et al., 2013). Identification of physiological substrates of many known and newly discovered P450s is 
mostly unsolved (Werck-Reichhart and Feyereisen, 2000), despite being extremely important for 
human health and relevant to biotechnology. Up to now, many human P450-mediated diseases have 
been identified (Pikuleva and Waterman, 2013). Some of these enzymes are also known to be 
involved in different reactions such as steroidogenic P450s that are capable of converting drugs 
(Schiffer et al., 2016a, 2016b). Therefore, a good understanding of P450 functions is required for 
successful drug design. The knowledge of their physiological role can also provide novel strategies to 
current therapies for the treatment of diseases caused by resistant pathogenic strains such as 
Mycobacterium tuberculosis (M. tuberculosis), whose genome encodes 20 P450s. Among them, 
CYP121A1 was found to be crucial for bacterial growth and now represents a therapeutic target (Ortiz 
de Montellano, 2018).     
1.1.5 Biotechnological importance and applications 
 
Regio- and stereo-selective oxyfunctionalization of non-active C-H bonds in organic molecules is 
very important for synthetic applications (Wong, 1998). Controlled oxidation of such bonds is, 
however, difficult to perform by chemical methods due to the C-H bond strength, the presence of 
several C-H bonds with similar bond energies in organic molecules, and the overoxidation reactions 
(Fasan, 2012; Lewis et al., 2011). P450s are able to attack chemically inert bonds and functionalize 
molecules often with high regio- and stereo-selectivity. Moreover, in contrast to chemical processes, 
these natural catalysts do not require several reaction steps or many reagents, and perform catalytic 
reactions under mild conditions (Girhard et al., 2015). Due to several advantages over organic 
synthesis, P450 enzymes, especially from prokaryotes, are attractive for biotechnology as potential 
producers of valuable compounds. As mentioned before, soluble bacterial P450s are robust enzymes, 
and are easier to overproduce and purify, in contrast to the membrane-bound ones from eukaryotes 
(Virus and Bernhardt, 2008). Although the physiological substrates are mostly not known, they are 
able to convert diverse biotechnologically and pharmaceutically important compounds, producing 
drugs, human drug metabolites, vitamins, flavors and fragrances (Sakaki, 2012). A fascinating 
example of industrial application of a prokaryotic P450 is 6′β-hydroxylation of a lead statin 
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compound, compactin, into the cholesterol-lowering drug pravastatin by CYP105A3 (Sakaki, 2012; 
Watanabe et al., 1995). Other biotechnologically highly relevant bacterial P450-based reactions 
include 25-hydroxylation and 1α,25-dihydroxylation of vitamin D3 by several P450s such as 
CYP105A1 from S. griseolus (Sugimoto et al., 2008). In addition to known high-value compounds, 
bacterial P450 enzymes can also produce novel oxyfunctionalized chemical structures which appear 
to be promising for application in different fields. This follows from the fact that introduction of one 
hydroxyl group often strongly changes the properties of the compound, such as its solubility and 
biological activity (Donova and Egorova, 2012; Sakaki, 2012).  
In spite of implementing many valuable reactions, practical application of P450 enzymes is still 
limited (Julsing et al., 2008, Bernhardt and Urlacher, 2014). The limiting factors are the multi-
component nature of these biocatalysts, inefficient electron transfer inside non-natural P450 systems, 
requirement of the expensive cofactor NAD(P)H in stoichiometric amounts, low catalytic activity of 
P450s, and low solubility of substrates in water (Bernhardt and Urlacher, 2014). On the one hand, 
there are open questions related to the biocatalysis such as electron transfer mechanism in P450 
systems, however, on the other hand, several strategies have been reported in order to overcome the 
aforementioned restrictions. For example, protein engineering methods can be applied to improve the 
catalytic activity of P450 (Wong, 1998). For sufficient electron supply, redox proteins can be replaced 
by electrodes as it was shown for bacterial and mammalian systems CYP101A1, CYP102A1, 
CYP17A1 and CYP2E1 (Estabrook et al., 1996; Sadeghi et al., 2011; Shumyantseva et al., 2005). 
Sufficient supply of NAD(P)H can be ensured by its regeneration using whole-cell systems, which are 
also generally favored for biotechnological purposes over isolated enzymes (Straathof et al., 2002). 
Common limitations of using P450-based whole-cell systems are complicated substrate transport into 
cells as well as substrate and product toxicity (Bernhardt and Urlacher, 2014). These important issues 
need to be thoroughly investigated for a particular P450 system in order to develop novel attractive 
systems for biotechnological processes. For example, limited substrate transport into the cell can be 
overcome using membrane permeabilizing agents (Janocha and Bernhardt, 2013), crude cell extracts 
(Zehentgruber et al., 2010) or by implementation of suitable host organism with uptake capability of a 
particular substrate (Bleif et al., 2012). 
1.2 Prokaryotic cytochrome P450s  
 
With about 3000 members, the prokaryotic P450s represent a much smaller group compared to over 
35000 representatives of eukaryotes (Nelson, 2018). They are classified within CYP101-CYP299 and 
CYP1001-CYP1407 families with an exception of CYP51. The vast majority of them originates from 
bacteria, and only three families CYP109, CYP147 and CYP197 are shared with bacterial and 
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archaeal P450 enzymes (Nelson, 2018). Despite their relatively low number, bacterial P450s have 
several advantages over eukaryotic counterparts, thus being essential for P450 research. They are 
soluble proteins lacking the hydrophobic membrane anchor, most of them exhibit higher stability and 
activity than eukaryotic P450s and, therefore, they are easier to handle and crystallize (Munro et al., 
2002; Urlacher and Eiben, 2006). It is not surprising that the most studied P450s, CYP101A1 
(P450CAM) and CYP102A1 (BM3), have bacterial origin. The first crystal structures were derived 
from these two P450s (Poulos et al., 1985, 1987; Ravichandran et al., 1993). In general, the huge part 
of structural and mechanistic knowledge on P450 enzymes is derived from these two bacterial 
proteins. To date, over 100 crystal structures of CYP102A1 have been reported (Janocha et al., 2016). 
Table 2 shows a short overview of important prokaryotic P450s and their known catalytic activities. 
Although many of them have been investigated since many years, the knowledge about their 
physiological function and natural redox partners is still missing in most cases. The selected examples 
include P450s from Amycolatopsis orientalis (A. orientalis), contributing to the vancomycin 
biosynthetic pathway and performing one of the unusual P450 reactions, oxidative phenol coupling, 
from N. aromaticivorans metabolizing aromatic hydrocarbons, as well as remarkable representatives 
from S. cellulosum, B. subtilis, Pseudomonas putida (P. putida) and Streptomyces sp. Other important 
examples comprise P450s originating from M. tuberculosis, highly interesting ones for therapeutic 
purposes (Souter et al., 2000), and from B. megaterium that are of considerable biotechnological 
importance (Schmitz et al., 2018; Whitehouse et al., 2012).  
There are five identified and partially characterized P450s from three different families of B. 
megaterium up to date: CYP102A1, CYP106A1, CYP106A2, CYP109E1 and CYP109A2 (Table 2). 
CYP102A1 and CYP106A2 have been identified about forty years ago and are still extensively 
studied (Berg et al., 1976, Narhi and Fulco, 1982). CYP102A1 from ATCC14581 is a fatty acid 
hydroxylase and an extraordinary member of the P450 superfamily, having a self-sufficient 
flavocytochrome nature as well as the highest coupling efficiencies and catalytic turnover (>3000 min
-
1
) among all known P450s (Furuya and Kino, 2010; Narhi and Fulco, 1982; Whitehouse et al., 2012). 
This enzyme has been a subject of numerous protein engineering studies. Its diverse mutants are able 
to accept a variety of other substrates such as drugs, terpenes and gaseous alkanes (Whitehouse et al., 
2012). CYP106A2 is a highly interesting steroid hydroxylase that is important for this work, and 
together with CYP109E1 will be discussed in detail below. CYP109E1, CYP109A2 and CYP106A1 
from DSM319 are relatively new members of the B. megaterium subfamily, identified after the 
genome sequencing of the strain (Brill, 2013; Eppinger et al., 2011). 
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Table 2. Selected examples of P450s from prokaryotic organisms with known characteristics  
Organism Activity  Reference 
Amycolatopsis 
orientalis 
CYP105AS1 – compactin hydroxylase  
CYP105EBH – epothilone B hydroxylase  
CYP165A1/B1/C1 – oxidative phenol 
coupling (vancomycin biosynthesis) 
(Basch and Chiang, 2007; 
Bischoff et al., 2005; McLean 
et al., 2015; Urlacher, 2010) 
Bacillus 
megaterium 
CYP102A1 – fatty acid hydroxylase 
CYP106A1/A2 – steroid hydroxylase 
CYP109E1/A2 – vitamin D3 hydroxylase  
(Berg and Rafter, 1981; Brill, 
2013; Narhi and Fulco, 1982) 
Bacillus subtilis CYP109B1 – fatty acid/terpene oxidase   
CYP102A2/3 – fatty acid hydroxylase 
P450 Biol – biotin synthesis  
(Girhard et al., 2010; Green et 
al., 2001; Gustafsson et al., 
2004) 
Mycobacterium 
tuberculosis 
CYP51B1 – sterol 14α-demethylase 
CYP121A1 – intramolecular C-C bond 
formation 
CYP124A1/125A1/142A1 – cholesterol / 
cholest-4-en-3-one oxidase  
(Belin et al., 2009; Horiuchi et 
al., 1998; Johnston et al., 
2010; McLean et al., 2009; 
Ouellet et al., 2010)  
Novosphingobium 
aromaticivorans 
CYP101B1/108D1 – aromatic hydrocarbon 
hydroxylase; CYP101B1 – norisoprenoid 
oxidase   
(Bell and Wong, 2007; Bell et 
al., 2012; Hall and Bell, 2014) 
Pseudumonas 
putida 
CYP101A1 – camphor 5-hydroxylase 
CYP111A1 – linalool 8-hydroxylase  
(Katagiri et al., 1968; Ullah et 
al., 1990) 
Sorangium 
cellulosum 
CYP109C1/C2/D1 – fatty acid hydroxylase 
CYP167A1 – epothilone D oxidase  
CYP260A1 – steroid 1α-hydroxylase     
CYP260A1/CYP264B1 – sesquiterpene 
oxidase 
CYP260B1/CYP267B1 – norisoprenoid 
oxidase 
CYP267A1/B1 – drug metabolizer  
(Kern et al., 2015, 2016, 
Khatri et al., 2010, 2013; 
Litzenburger and Bernhardt, 
2016; Ringle, 2013; Schifrin et 
al., 2015) 
Streptomyces 
species 
CYP105A3 – compactin hydroxylase   
CYP105A1 – vitamin D3 hydroxylase 
(Sugimoto et al., 2008; 
Watanabe et al., 1995) 
 
1.2.1 CYP106A2 
 
CYP106A2 from B. megaterium ATCC13368 is a bacterial steroid hydroxylase, identified in the late 
1970s (Berg et al., 1975, 1976, 1979). The enzyme was cloned, sequenced and heterologously 
expressed in E. coli as well as in B. subtilis (Rauschenbach et al., 1993). The first substrate identified 
for CYP106A2 was progesterone, which was mainly converted to 15β-hydroxyprogesterone. Various 
other 3-oxo-Δ4 steroids, such as 11-deoxycortisol (RSS) and testosterone, were also found to be 15β-
hydroxylated by CYP106A2. Therefore, this enzyme was characterized as the first bacterial steroid 
15β-hydroxylase (Berg et al., 1976; Kiss et al., 2015). Furthermore, other hydroxylation positions 
were identified with related substrates, such as 6β, 7β, 9α and 11α in the gonane and 7β in ursane 
skeleton. Interestingly, 12α and 12β, 7β and 11α hydroxylation positions were identified for abietane 
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and dammarane terpenoid cores, respectively (for review see: Schmitz et al., 2018). Due to its 
versatility and high regio-and stereo-specificity, the enzyme has been intensively studied for four 
decades. HTS methods, using more than 16000 synthetic compounds and 500 bioactive natural 
products, identified various compounds as novel substrates for CYP106A2 such as the pentacyclic 
triterpene 11-keto-β-boswellic acid (KBA) (Bleif et al., 2012), the triterpenoid dipterocarpol (Schmitz 
et al., 2012), the diterpene resin acid abietic acid (Bleif et al., 2011) and several other compounds with 
biotechnological or pharmaceutical importance (Schmitz et al., 2018). Despite the number of 
identified substrates of CYP106A2, the information about the physiological role of this P450 and its 
natural substrate(s) is still missing (Schmitz et al., 2012). In contrast, the natural redox partners of 
CYP106A2, a NADPH-dependent FMN-containing flavoprotein (megaredoxin reductase) as well as 
an iron-sulfur protein (megaredoxin) have been described, although, they have not been cloned yet 
(Berg et al., 1976; Bureik and Bernhardt, 2007). It has been shown that the activity of CYP106A2 can 
be reconstituted using an adrenal protein pair, adrenodoxin (Adx) and adrenodoxin reduxtase (AdR) 
and redox systems from B. subtilis and P. putida (Agematu et al., 2006; Rauschenbach et al., 1993; 
Simgen et al., 2000; Virus and Bernhardt, 2008). In addition, the electron transfer protein etp1 from 
Schizosaccharomyces pombe (S. pombe) was found to interact with CYP106A2 effectively (Bureik et 
al., 2002).  
Effective protein engineering work on CYP106A2 was done using directed evolution as well as 
rational design strategies to increase the catalytic activity and change the regio-selectivity of 
progesterone hydroxylation from 15β to pharmaceutically important 11α, 9α and 6β positions. A study 
on two generations of directed evolution using fluorescence-based HTS methods revealed mutants 
with 4- and 1.4-fold improved kcat/KM for hydroxylation towards RSS and progesterone, respectively 
(Virus and Bernhardt, 2008). Great shifts of regio-selectivity from 15β to 11α and 9α of CYP106A2 
towards progesterone was achieved by mutants created through saturation and site-directed 
mutagenesis based on a CYP106A2 homology model (Lisurek et al., 2008; Nguyen et al., 2012; 
Nikolaus et al., 2017). The X-ray structure of CYP106A2 was recently solved, showing a mainly 
hydrophobic active site and several side chains capable of forming hydrogen bonds and salt bridges 
with its substrates (Janocha et al., 2016). Furthermore, a single mutant based on docking of 
progesterone to the active site of CYP106A2, showed an increase of 6β-hydroxylation activity of 
progesterone from 8.7 (wild type) to 82.7% (Nikolaus et al., 2017). 
1.2.2 CYP109E1 
 
CYP109E1 is a recently identified P450, encoded by the genome of B. megaterium strain DSM319 
(Brill, 2013). In contrast to CYP106A2, only little is known about this P450. Testosterone induced a 
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type I spectral shift and has been converted to mainly 16β-hydroxytestosterone by this enzyme. Thus, 
CYP109E1 was characterized as the first bacterial wild type steroid 16β-hydroxylase (Jóźwik et al., 
2016). Three other compounds, vitamin D3, nootkatone and isolongifolen-9-one, were further 
identified as its substrates (Brill, 2013). It was shown that vitamin D3 was converted by CYP109E1 
into 6 products, whereas the enzyme was selective towards two sesquiterpene substrates.     
CYP109E1 was successfully heterologously expressed in E. coli, purified and crystallized in 
substrate-free as well as ligand- and substrate-bound forms (Jóźwik et al., 2016). Interestingly, among 
the tested 13 steroids, only testosterone showed considerable in vitro turnover by CYP109E1 using 
bovine AdR and truncated Adx4-108 as redox proteins. Although some of the screened steroidal 
compounds were able to induce a type I shift of the heme iron, they were not converted by CYP109E1 
or the conversion was negligible. The active site pocket of the substrate-free CYP109E1 was found to 
be constructed by mainly hydrophobic amino acids, whereas the residues near the substrate entrance 
channel are mostly polar and charged. The structural environment of the active site is similar to the 
six SRSs identified for CYP101A1 (Gotoh, 1992): the BC loop (SRS1), part of F (SRS2) and G 
(SRS3) helices, the middle region of the I helix (SRS4), the region between the K helix and β5 strand 
(SRS5) and the β9-10 turn (SRS6) (Jóźwik et al., 2016). The substrate/ligand binding narrows the 
active site pocket and causes large orientational changes of the FG loop and helices F and G (Jóźwik 
et al., 2016). The I helix at residues 242-246 widens locally, allowing steroids to go closer to the 
heme. Additionally, water molecules were found at the interface of helices I and E. It is believed that 
they, together with residues A242, G243, T246-248, build a hydrogen-bonded proton delivery 
pathway (Denisov and Sligar, 2015; Jóźwik et al., 2016). Based on the results of structural modeling, 
several single alanine mutants have been created to check the importance of identified residues for 
testosterone binding and hydroxylation. The loss of the catalytic activity caused by V169A and I241A 
substitutions indicated their importance for productive binding of testosterone. The mutant of the 
highly conserved threonine at position 246 showed drastically decreased activity, supporting the 
hypothesis that this residue contributes in proton delivery and oxygen activation (Jóźwik et al., 2016).  
1.2.3 Bacillus megaterium as expression host for P450 systems  
 
The Gram-positive rod-shaped soil bacterium B. megaterium gained popularity in the field of 
biotechnology due to its GRAS nature, ability to grow on different cheap media, high capacity for 
production of important substances, e.g. heterologous proteins and due to enzymes encoded by its 
genome such as the very successful representative of the P450 superfamily, CYP102A1 and the 
steroid hydroxylases, CYP106A1/A2 (Brill, 2013; Bunk et al., 2010; Kiss et al., 2015a; Rygus and 
Hillen, 1992; Vary et al., 2007; Whitehouse et al., 2012). Moreover, B. megaterium is found to be a 
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suitable host for the coexpression of both endogenous and mammalian P450s and their redox partners. 
The resulting P450 whole-cell systems based on the MS941 strain, were found to be suitable 
biocatalysts for cost-effective production of various important compounds in several studies by our 
group (Bleif et al., 2012; Brill et al., 2014; Ehrhardt et al., 2016a, 2016b; Gerber et al., 2015; Kiss et 
al., 2015b). For example, whole-cell systems overexpressing CYP106A1 or CYP106A2 produced 
pharmaceutically important metabolites of KBA, cyproterone acetate as well as various 
hydroxysteroids (Bleif et al., 2012; Brill et al., 2014; Kiss et al., 2015a). Interestingly, the activity of 
the mammalian mitochondrial P450 systems containing CYP11A1 and CYP27A1 supported by 
adrenal redox chain (AdR, Adx) was successfully reproduced in B. megaterium, showing effective 
side-chain cleavage and 27-hydroxylation of cholesterol, respectively (Ehrhardt et al., 2016a; Gerber 
et al., 2015). The established whole-cell systems of mammalian P450s in B. megaterium showed 
efficient bioconversions, and thus emphasized the high potential of this bacterium in P450-based 
biocatalysis. Since bacterial P450 systems are soluble and generally easier to express, endogenous 
P450-based systems are expected to be even more promising for biotechnological applications. The 
CYP106A2-based B. megaterium system has been successfully scaled up at a 400 mL scale for 
cyproterone acetate conversion, yielding 0.43 g/L product, 15β-hydroxycyproterone acetate using a 
bench-top bioreactor (Kiss et al., 2015b). It is important to note, that in this whole-cell system only 
CYP106A2 was overexpressed and its activity was successfully supported by redox 
partners endogenously synthesized in the MS941 strain. Although several redox proteins of this strain 
have been identified such as Fdxs and BmCPR (Brill et al., 2014; Milhim et al., 2016b), the natural 
partners for endogenous P450s remain unknown. Moreover, the physiological substrates of the P450s 
have not been identified yet, thus the potential of this bacterium for the production of 
oxyfunctionalized molecules is not fully discovered.  
1.3 Aims 
 
The current work aims to study the catalysis of various biotechnologically and pharmaceutically 
important compounds by two functionally different P450 enzymes from B. megaterium, CYP106A2 
and CYP109E1.  
CYP106A2 is one of the few characterized bacterial steroid hydroxylases showing high potential for 
biotechnological applications. Prednisone and dexamethasone, synthetic steroidal anti-inflammatory 
and immunosuppressive drugs, have been identified previously as substrates of CYP106A2. Since 
hydroxylation is one of the important reactions for steroid functionalization, the goal is to investigate 
CYP106A2-mediated biotransformations of prednisone and dexamethasone in order to generate novel 
steroidal drug candidates or important intermediates for further modification of steroid structure. The 
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reactions will be investigated in vitro with a reconstituted CYP106A2 system as well as with binding 
titrations in order to identify product patterns, the kinetic parameters (kcat, KM) and the dissociation 
constant (Kd). The conversion of the substrates will be further investigated with several CYP106A2-
based B. megaterium strains. In case of a successful in vivo turnover of prednisone and 
dexamethasone by CYP106A2, preparative whole-cell biotransformations will be performed with 
subsequent product purification for the structural identification of steroid derivatives via nuclear 
magnetic resonance (NMR) analysis.  
CYP109E1 is a recently identified P450 and there is only little known about its substrates and 
catalytic functions. Therefore, the aim is to expand the substrate range of CYP109E1 and evaluate its 
potential for synthetic applications. A focused library of compounds will be screened through 
monitoring high-spin shifts spectroscopically and in vitro conversions. The conversions will be 
analyzed by high performance liquid chromatography (HPLC) or gas chromatography-mass 
spectrometry (GC-MS). Biotransformations of the newest substrates, selectively converted in vitro, 
will be investigated using a CYP109E1-based B. megaterium whole-cell biocatalyst in order to test 
the system for the ability to reproduce the in vitro conversion and to generate the products on 
milligram-scale. The reaction products should be isolated for their structural elucidation in order to 
characterize the new CYP109E1-mediated reactions.  
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2. Scientific articles 
 
2.1 Putkaradze et al. 2017a 
 
Biotransformation of prednisone and dexamethasone by cytochrome P450 based 
systems - Identification of new potential drug candidates 
 
Natalia Putkaradze, Flora Marta Kiss, Daniela Schmitz, Josef Zapp, Michael C.Hutter, Rita Bernhardt 
2017, Journal of Biotechnology. 242:101-110 
DOI: 10.1016/j.jbiotec.2016.12.011 
Reprinted with the permission of Elsevier. 
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2.2 Abdulmughni et al. 2017 
 
Characterization of cytochrome P450 CYP109E1 from Bacillus megaterium as a novel 
vitamin D3 hydroxylase 
 
Ammar Abdulmughni, Ilona K. Jóźwik, Natalia Putkaradze, Elisa Brill, Josef Zapp, Andy-Mark 
W.H.Thunnissen, Frank Hannemann, Rita Bernhardt  
2017, Journal of Biotechnology. 243:38-47 
DOI: 10.1016/j.jbiotec.2016.12.023 
Reprinted with the permission of Elsevier. 
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2.3 Putkaradze et al. 2017b 
 
CYP109E1 is a novel versatile statin and terpene oxidase from Bacillus megaterium 
 
Natalia Putkaradze, Martin Litzenburger, Ammar Abdulmughni, Mohammed Milhim, Elisa Brill, 
Frank Hannemann, Rita Bernhardt 
 
2017, Applied Microbiology and Biotechnology. 101(23-24):8379-8393 
  
DOI: 10.1007/s00253-017-8552-6 
 
Reprinted with the permission of Springer Science and Business Media. 
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2.4     Milhim et al. 2016 
 
Identification of a new plasmid-encoded cytochrome P450 CYP107DY1 from Bacillus 
megaterium with a catalytic activity towards mevastatin 
 
Mohammed Milhim, Natalia Putkaradze, Ammar Abdulmughni, Fredy Kern, Philip Hartz, Rita 
Bernhardt 
2016, Journal of Biotechnology. 240:68-75 
DOI: 10.1016/j.jbiotec.2016.11.002 
Reprinted with the permission of Elsevier. 
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3. Discussion and outlook 
 
Cytochrome P450s represent a very important and diverse enzyme superfamily. They are widespread 
in nature and are able to metabolize structurally as well as functionally different compounds from the 
small aroma terpenoid camphor (MW ~ 150) to much bigger molecules such as the anti-tumor agent 
epothilone D (MW ~ 500) or the drug cyclosporine A (MW ~ 1200) (Combalbert et al., 1989; 
Katagiri et al., 1968; Ogura et al., 2004). Despite their huge number and sequence variety, P450s can 
be divided into the following groups: (i) xenobiotic-metabolizing P450s involved in degradation of 
drugs, insecticides, herbicides and other xenobiotics, (ii) P450s playing key roles in anabolic 
metabolic transformations such as the biosynthesis of hormones and active signaling agents, and (iii) 
extremely diverse microbial P450s performing oxidative tailoring of a wide array of chemical 
structures. The latter group is pharmaceutically and biotechnologically highly interesting since its 
members can be used as model systems for studying human P450s associated with various diseases 
(Kelly and Kelly, 2013) and as biotechnological tools for low-cost production of valuable compounds. 
In contrast to mammalian or plant P450s, microbial P450s have several advantages: they are cytosolic 
soluble proteins, thus easier to overproduce and handle, and they exhibit higher catalytic activities 
(Bernhardt, 2006; Bernhardt and Urlacher, 2014). Thanks to sequencing projects of microbial 
genomes and metagenomes, the number of microbial P450s continues increasing constantly. Despite 
being a challenging task, identifying the function of these novel proteins is highly desirable due to 
their potential for synthetic applications as well as in drug discovery (Kandel et al., 2014). From a 
biotechnological perspective, the establishment of novel P450-based microbial whole-cell biocatalysts 
is more desirable than using purified or immobilized enzymes. The main reasons are the multi-
enzyme nature of P450 systems and their continuous requirement of reducing equivalents. In whole-
cell systems, functional P450 and electron mediator proteins can be overproduced and exploited in 
vivo for biotransformation without the need of cost- and time-consuming purification procedures of 
component proteins. At the same time, the primary electron donor, NAD(P)H, can be provided 
through the central metabolism of the organism and, in case of its limitation, can be restored by 
introducing an enzymatic regenerating system (Bernhardt and Urlacher, 2014). In this context, B. 
megaterium is a highly interesting bacterium. On the one hand, several strains of this microorganism 
encode important well-known and novel poorly-characterized P450s as well as their redox proteins 
(Berg and Rafter, 1981; Brill et al., 2014; Milhim et al., 2016b; Narhi and Fulco, 1987). Examples of 
P450s originating from B. megaterium are a fatty acid hydroxylase CYP102A1, a steroid hydroxylase 
CYP106A2 as well as a newly identified vitamin D3 hydroxylase CYP109E1 and a compactin 
hydroxylase CYP107DY1 (Brill, 2013; Fulco, 1991; Milhim et al., 2016a; Whitehouse et al., 2012). 
Besides that, the bacterium has been shown to be a useful host, overexpressing various P450 systems 
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even from mammals (Brill et al., 2014; Bleif et al., 2012; Kiss et al., 2015a; Gerber et al., 2015). 
Furthermore, human CYP11A1- and CYP27A1-based systems in combination with bovine redox 
partners, established recently in B. megaterium MS941 strain, showed higher product yields in 
comparison to similar recombinant systems in Saccharomyces cerevisiae and Escherichia coli 
(Duport et al., 1998; Ehrhardt et al., 2016a; Gerber et al., 2015; Salamanca-Pinzón and Guengerich, 
2011). It is not surprising that B. megaterium systems based on endogenous soluble P450s are also 
effective. For example, ATCC13368 strain, the native host of CYP106A2 was successfully applied 
for the preparative conversion of dehydroepiandrosterone into its pharmaceutically important 7β-
hydroxymetabolite (Schmitz et al., 2014). In other studies, MS941 strains, overexpressing only P450s, 
or P450 with semi-homologous (endogenous Fdx, Arh1 from S. pombe) or heterologous (bovine AdR, 
Adx) redox chains, were applied for regio-selective hydroxylations of various steroids, di- and tri-
terpenes (Bleif et al., 2011, 2012; Brill et al., 2014; Kiss et al., 2015a).      
CYP106A2 and CYP109E1 are interesting and functionally different P450 monooxygenases from B. 
megaterium. CYP106A2 is a versatile steroid hydroxylase, whereas CYP109E1 is a vitamin D3 
hydroxylase with limited catalytic activity towards common steroidal compounds. Both enzymes are 
soluble, belong to the class I P450 systems, and have been shown to be successfully overexpressed in 
B. megaterium as well as heterologously in E. coli (Bleif et al., 2012; Jóźwik et al., 2016; Schmitz et 
al., 2012). Since their physiological role and substrates remain unknown, it is attractive to further 
characterize these P450s to explore biotechnologically desirable reactions and establish novel P450-
based effective, eco-friendly and low-cost whole-cell systems for the production of valuable products 
in reasonable amounts. CYP106A2- and CYP109E1-based biotransformations of structurally diverse 
compounds are studied in this work. Due to the fact that CYP106A2 is being investigated since many 
years, several studies have been conducted to identify its substrate range and, consequently, a number 
of various compounds has been screened and reported as substrates (Schmitz et al., 2018). This work 
aimed for a detailed characterization of biotransformation of the pharmaceutically highly important 
steroids prednisone and dexamethasone in order to produce hydroxylated products using several 
CYP106A2-based whole-cell systems. In contrast to CYP106A2, CYP109E1 has been investigated 
for only a few years, resulting in the identification of four substrates so far (Brill, 2013). Therefore, 
this work aimed to further characterize CYP109E1 by exploring novel potential substrates and to 
establish whole-cell systems for the production of important oxygenated products.  
3.1  Production of glucocorticoid drug derivatives 
 
Prednisone and dexamethasone are synthetic steroidal (glucocorticoid) drugs (Scheme 1 in Chapter 
2.1), identified as substrates of CYP106A2 that show a type I spectral shift and in vitro conversion in 
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previous study (Schmitz et al., 2014). However, the reaction products have not been identified. Due to 
the fact that CYP106A2 is a versatile steroid hydroxylase, and hydroxysteroids are important for drug 
design and development approaches, the conversion of both drugs was characterized in detail in this 
study (Chapter 2.1). 
Investigating binding titrations with difference spectroscopy (Figure 1 in Chapter 2.1) and in vitro 
kinetics (Figure 3 in Chapter 2.1) showed tighter binding affinity of dexamethasone (Kd=189 µM, 
KM=115 µM) to CYP106A2 compared with that of prednisone (Kd=434 µM, KM=185 µM). Despite 
the stronger binding, the catalytic activity of CYP106A2 towards dexamethasone was found to be 
remarkably lower (kcat=8 min
-1
) than towards prednisone (kcat=116 min
-1
). It was shown that 
CYP106A2 hydroxylates both glucocorticoids in a highly regio- and stereo-selective manner, yielding 
exclusively one product using bovine AdR and Adx4-108 as redox partners (Figure 2 in Chapter 2.1). 
The CYP106A2-mediated conversions were further investigated by B. megaterium whole-cell systems 
in order to reproduce the in vitro activity and isolate the products for the structure identification via 
NMR. Significant differences have been observed between prednisone and dexamethasone 
conversions using several CYP106A2-based B. megaterium systems. In case of dexamethasone, the 
product pattern in vivo was similar to in vitro, whereas for prednisone, one product was identified in 
vitro and up to four in vivo using the different strains (Figures 2 and 5 in Chapter 2.1). The natural 
host strain of CYP106A2, ATCC13368 (ATCC_wt), showed higher selectivity and activity towards 
prednisone than the MS941 strains that overexpressed either CYP106A2 (MS941_C) or CYP106A2 
with adrenal redox partners (MS941_CAA) (Figure 6 in Chapter 2.1). The NMR analysis of the 
obtained prednisone products revealed already reported as well as new derivatives that were modified 
at four sites in the steroid structure: 15β-hydroxyprednisone, 15β, 17, 21-trihydroxy-preg-4-en-
3,11,20-trione, 20β-dihydrocortisone, cortisone, 15β,17,20β,21-tetrahydroxy-preg-4-en-3,11-dione 
and 15β,17,20β,21-tetrahydroxy-preg-1,4-dien-3,11-dione (Figure 6). In addition, prednisone was 
found to be converted to 20β-dihydrocortisone via the intermediate cortisone also with MS941_wt 
control strain that does not encode CYP106A2. This result indicated that the structural modifications 
at positions C20 and C1-C2 are carried out by endogenous enzymes of B. megaterium strains such as 
FabG (Gerber et al., 2016). In contrast to prednisone, dexamethasone was not converted by 
MS941_wt (CYP106A2-independent) strain and its conversion by different CYP106A2-based whole-
cells yielded one product, 15β-hydroxydexamethasone. Thus, the obtained results identified the 15β-
hydroxylase activity of CYP106A2 towards both investigated substrates. In silico studies using the 
crystal structure of CYP106A2 (Janocha et al., 2016) provided an explanation of the aforementioned 
lower activity of CYP106A2 towards dexamethasone. It was suggested that the radical formed after 
hydrogen abstraction at C15 can migrate to the energetically more favorable position 16 (Figure 4 in 
DISCUSSION AND OUTLOOK 
__________________________________________________________________________________ 
 
91 
 
Chapter 2.1), causing the radical depletion and, therefore, lowering the 15β-hydroxylation activity of 
P450 towards this substrate. 
 
Figure 6. Chemical structures of prednisone derivatives produced by different B. megaterium strains. 
Prednisone is depicted in the middle (positions modified in its structure are numbered). Site of modification for 
a particular product is shown with a red arrow. P1:15β-hydroxyprednisone, P2: 15β, 17, 21-trihydroxy-preg-4-
en-3,11,20-trione, P3: 20β-dihydrocortisone, P4:15β,17,20β,21-tetrahydroxy-preg-4-en-3,11-dione, 
P5:15β,17,20β,21-tetrahydroxy-preg-1,4-dien-3,11-dione, P6:cortisone. Figure adapted from Putkaradze et al. 
(2017a)  
To sum up, CYP106A2 was identified as a highly selective prednisone and dexamethasone 15β-
hydroxylase. This enzyme provides a possibility to generate 15β-hydroxyprednisone and 15β-
hydroxydexamethasone using a reconstituted in vitro system as well as B. megaterium whole-cell 
biocatalysts. Due to the high selectivity of dexamethasone conversion in vivo, the investigated 
CYP106A2-based strains can be applied for milligram-scale production of 15β-
hydroxydexamethasone and can be further studied to optimize the productivity. In contrast to 
dexamethasone, low selectivity was observed for prednisone conversion in vivo, yielding two new 
prednisone metabolites, 15β,17,20β,21-tetrahydroxy-preg-4-en-3,11-dione and 15β,17,20β,21-
tetrahydroxy-preg-1,4-dien-3,11-dione, in addition to the 15β-hydroxylated product. Therefore, for 
the highly selective and low-cost production of 15β-hydroxyprednisone, a CYP106A2-based system 
in other microorganisms such as E. coli should be established. 15β-hydroxydexamethasone and 
prednisone derivatives (15β-hydroxyprednisone, 15β,17,20β,21-tetrahydroxy-preg-4-en-3,11-dione 
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and 15β,17,20β,21-tetrahydroxy-preg-1,4-dien-3,11-dione), generated in this study, are 
pharmaceutically interesting uncharacterized compounds. They can be used for biological activity 
studies and as lead steroidal compounds for further modification. To shift the hydroxylation activity 
of CYP106A2 from 15β to pharmaceutically important positions such as 9α (for prednisone) or 6β 
(for both substrates) protein engineering strategies can be applied (Nikolaus et al., 2017; Nguyen et 
al., 2012). 
3.2  CYP109E1 as versatile biocatalyst 
 
A novel P450 from B. megaterium, CYP109E1, has been identified as testosterone and vitamin D3 
hydroxylase in previous and our parallel studies (Abdulmughni et al., 2017; Jóźwik et al., 2016). 
Interestingly, CYP109E1 is phylogenetically related to the steroid hydroxylase CYP106A1; however, 
in contrast to CYP106A1, of the tested 3-oxo-Δ4-steroids it converts only testosterone efficiently 
(Table 3). Some steroids, such as corticosterone and dexamethasone, bind to the enzyme and induce a 
high-spin shift, nevertheless they are not metabolized. Considering the steroid structures and 
experimental data, it can be assumed that the hydroxyl group at position C17 (present in cortisone, 
cortisol, RSS, prednisone, dexamethasone and prednisolone) restricts the binding to the heme when 
there is no methyl group at position C16 (present in dexamethasone). In addition, the methyl group at 
position C10 in testosterone (not present in 19-nortestosterone) seems crucial for binding and catalytic 
activity of CYP109E1. The structural (crystallographic), computational (MD simulations) and 
experimental (site-directed mutagenesis) results for corticosterone and testosterone binding and 
conversion provided important insights on the interactions of CYP109E1 with these steroids. In the 
active site, the steroid compounds are proposed to be orientated in two positions perpendicular to the 
heme plane so that in the first case the 3-keto group of steroids (A ring) is the closest to the heme and 
the C17 position is far away (unproductive binding mode) and vice versa (productive binding mode) 
(Jóźwik et al., 2016). The experimental data for another steroid-related substrate of CYP109E1, 
vitamin D3, suggests similar binding orientations showing either 1-hydroxylation (analogously to the 
A ring of steroids) or predominant 24/25-hydroxylations (side chain) (Abdulmughni et al., 2017). 
Interestingly, vitamin D3 is not able to displace the water ligand of the heme; however, it can be 
converted by CYP109E1. Additionally, two smaller molecules, nootkatone and isolongifolen-9-one, 
showed type I difference spectrum and were converted by CYP109E1 (Brill, 2013).  
With the goal to provide further insights concerning the substrate range and biotechnological potential 
of this important P450, several compounds have been tested as potential substrates. They have been 
selected based on two principles: 1) known substrates of CYP109 family enzymes and related 
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compounds (Furuya et al., 2009) (Scheme 1 in Chapter 2.3), and 2) compounds with methyl-
branched hydrocarbon chains such as that of vitamin D3 (Figure S1). As a result, the substrate range 
of CYP109E1 was expanded with many compounds that are significant for the biotechnological and 
pharmaceutical as well as fragrance industries (Table 3). Most of them showed a type I spin shift of 
CYP109E1 upon binding (Figures 1 and S1 in Chapter 2.3) and were successfully converted with 
high selectivities in vitro as well as in vivo (Figures 2 and 3 in Chapter 2.3). A B. megaterium 
CYP109E1-based system has been successfully utilized for the biotransformations of the novel 
compounds and for the isolation of the reaction products on milligram-scale for the structure 
identification via NMR spectrometry. An important statin drug (pravastatin), hydroxylated drug 
metabolites (6′β-hydroxy-lovastatin, 3′α-hydroxy-simvastatin and 4″-hydroxy-simvastatin) and 
several terpene derivatives (3-hydroxy-α-ionone, 4-hydroxy-β-ionone, 11,12-epoxy-nootkatone, 4(R)-
hydroxy-isolongifolen-9-one, 3-hydroxy-α-damascone, 4-hydroxy-β-damascone, 3,4-epoxy-β-
damascone and 2-hydroxy-β-damascenone) have been produced using a CYP109E1-based whole-cell 
biocatalyst (Putkaradze et al., 2017b). It is important to note, that CYP109E1 is the first enzyme to be 
identified as being capable of converting simvastatin to 4″-hydroxy-simvastatin as well as β-
damascenone to 2-hydroxy-β-damascenone, a novel compound, providing the possibility to easily 
synthesize and functionally characterize these molecules. Furthermore, this enzyme is able to perform 
one of the most important P450-based reactions on industrial scale, the conversion of a natural 
product, compactin, to pravastatin. Due to its observed wide substrate specificity, screening of a 
natural product library seems highly promising to identify new reactions of CYP109E1 as described 
for CYP106A2 in previous study (Schmitz et al., 2014). In addition, the CYP109E1-based system 
found to be effective in vivo, especially in producing the ionone derivatives, converting up to 200 μM 
α- and β-ionone almost completely within 2 h (Figure 3a and b in Chapter 2.3). Each conversion 
needs to be further investigated in order to identify suitable optimization strategies and enhance the 
productivity. It is noteworthy that B. megaterium cells, used in this study, are overexpressing 
CYP109E1 without redox partners and the activity of P450 is supported by endogenously synthesized 
unknown proteins. Therefore, the identification of the cognate redox partners and their coexpression 
together with CYP109E1 seems to be a very promising strategy to increase the productivity of the in 
vivo system.  
Five more compounds, cholesterol, 7-ketocholesterol, ergosterol, stigmasterol and vitamin D2 
(ergocalciferol), were selectively converted by CYP109E1 in vitro and were identified as its novel 
substrates (Figures S2a and S3). As previously mentioned, their structures are similar to vitamin D3 
having a steroidal or seco-steroidal core and a hydrocarbon side chain. Because of the reported narrow 
cavity of the active site with almost exclusively hydrophobic architecture near to heme and  
predominant 24(S)/25-hydroxylation activity towards vitamin D3 (Figure 3 in Chapter 2.2), 
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modifications at side-chain positions are also expected for other similar substrates. To prove this, the 
biotransformation of cholesterol by CYP109E1 has been further investigated. The in vitro experiment 
showed that cholesterol was converted by CYP109E1 to two main products with comparable 
selectivities (Figure S2a and b). The conversion was successfully reproduced in vivo (Figure S2c) and 
the reaction products have been isolated for structure elucidation by NMR (NMR data in Chapter 
5.1). 
Table 3. Overview of tested compounds for in vitro assays with CYP109E1 and all identified substrates. “n.d” 
not determined 
Compound Spin shift In vitro conversion Reference 
Testosterone yes yes (Brill, 2013) 
Vitamin D3 no yes (Brill, 2013) 
Nootkatone yes yes (Brill, 2013) 
Isolongifolen-9-one   yes yes (Brill, 2013) 
Androstenedione yes low (<10%) (Jóźwik et al., 2016) 
Cortisol no no (Jóźwik et al., 2016) 
Cortisone no no (Jóźwik et al., 2016) 
Corticosterone yes no (Jóźwik et al., 2016) 
DOC yes low (<7%) (Jóźwik et al., 2016) 
RSS no no (Jóźwik et al., 2016) 
Prednisone no no (Jóźwik et al., 2016) 
Dexamethasone yes no (Jóźwik et al., 2016) 
Prednisolone no no (Jóźwik et al., 2016) 
Progesterone no no (Jóźwik et al., 2016) 
Testosterone acetate yes low (<10%) (Jóźwik et al., 2016) 
19-nortestosterone no no (Jóźwik et al., 2016) 
Compactin yes yes this work 
Lovastatin yes yes this work 
Simvastatin yes yes this work 
Medroxyprogesterone acetate no no this work 
Norethisterone no no this work 
Norethisterone acetate no no this work 
α-ionone yes yes this work 
β-ionone yes yes this work 
α-damascone yes yes this work 
β-damascone yes yes this work 
β-damascenone yes yes this work 
Cholesterol n.d. yes this work 
7-ketocholesterol  n.d. yes this work 
Ergosterol n.d. yes this work 
Stigmasterol n.d. yes this work 
Vitamin D2 n.d. yes this work 
 
As expected, it was found that CYP109E1 is able to catalyze 24(S)- and 25-hydroxylations of 
cholesterol, similar to vitamin D3 (Figure 7). 24(S)- and 25-hydroxycholesterols are highly important 
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physiological oxysterols. They act as agonists of liver receptors LXRα and LXRβ (Berrodin et al., 
2010; Janowski et al., 1999) as well as ligands of the RAR-related orphan receptors RORα and RORγ 
(Mutemberezi et al., 2016). 24(S)-hydroxycholesterol is formed by CYP46A1 in the brain and it has 
also been suggested as a biomarker for neurodegenerative diseases (Leoni and Caccia, 2013), whereas 
25-hydroxycholesterol is synthesized by the enzyme cholesterol 25-hydroxylase and has been 
reported to have potent effects on the immune system (McDonald and Russell, 2010). The intensive 
research on the wide-ranging effects of the oxysterols demands their availability in sufficient amounts 
and makes systems producing these metabolites biotechnologically highly attractive. To date, the 
obtained oxysterols are highly expensive compounds: 24(S)-hydroxycholesterol is about 3300-fold 
and 25-hydroxycholesterol up to 500-fold more expensive than their precursor, cholesterol.  
 
Figure 7. Chemical structures of cholesterol and its metabolites produced by CYP109E1, elucidated by NMR 
spectrometry. P1: 24(S)-hydroxycholesterol, P2: 25-hydroxycholesterol 
 
Interestingly, the CYP109E1-based B. megaterium system used in our studies (Abdulmughni et al., 
2017; Putkaradze et al., 2017b) showed remarkably low activity towards cholesterol, yielding about 
20% conversion of 200 μM substrate after 48 h, which was not the case for other substrates such as 
vitamin D3. The reason of this can be a partial availability of cholesterol for CYP109E1 due to their 
different cellular localizations. As reported in previous study, cholesterol accumulates in poly-3-
hydroxybutyrate (PHB) bodies of B. megaterium (Gerber et al., 2015), whereas CYP109E1 is a 
soluble protein localized in the cytoplasm. Therefore, application of a B. megaterium strain, that lacks 
the ability to synthesize PHB bodies for CYP109E1-based whole-cell conversion of cholesterol, 
seems very promising to analyse this. As an alternative, a novel CYP109E1-based E. coli system was 
successfully established in this study showing 3.3-fold higher conversion of cholesterol compared 
with B. megaterium system (Figure S2d) and representing also even more promising basis for further 
improvement.  
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In summary, the substrate range of CYP109E1 was extended with 13 new compounds including 
statins (compactin, lovastatin and simvastatin), norisoprenoids (ionones, damascones and β-
damascenone), sterols (cholesterol, 7-ketocholesterol, ergosterol and stigmasterol) and a seco-steroid 
(vitamin D2). Most of the novel CYP109E1-dependent biotransformations were characterized in vitro 
as well as in vivo. This lead to identification of several biotechnologically interesting reactions (and 
two whole-cell systems), producing statin drug metabolites, terpene derivatives and important 
oxysterols. Apart from them, CYP109E1 was found to be able to catalyze a novel enzymatic reaction, 
4″-hydroxylation of simvastatin, and an industrially relevant transformation producing pravastatin. 
3.3    Towards engineering of CYP109E1 for pravastatin production 
 
Regio- and stereo-selective 6′β-hydroxylation of compactin to the drug pravastatin is a highly 
important reaction (Sakaki, 2012). As mentioned before, CYP109E1 has been identified as one of a 
few P450s capable of carrying out this biotransformation. It is important to note that this wild type 
enzyme can produce the pharmacologically active pravastatin in a highly stereo-selective manner 
(Scheme 2 in Chapter 2.3). Moreover, the CYP109E1-based whole-cell system, applied in this study, 
produced up to 14 mg/L pravastatin within 4 h, showing comparable productivity to other wild type 
systems, CYP105A3 (12.9 mg/L within 21 h) and CYP107DY1 (13.2 mg/L within 20 h), while 
increasing the space-time yield 5 times (Milhim et al., 2016a; Putkaradze et al., 2017b). This makes 
the CYP109E1-based system a good candidate for optimization in order to improve the pravastatin 
production. Despite showing high selectivity (82±5%), CYP109E1 activity towards compactin, both 
in vitro and in vivo, was shown to be remarkably lower in comparison with other statin substrates, e.g. 
lovastatin and simvastatin (Figures 2 and S2 in Chapter 2.3). Moreover, the determined dissociation 
constants showed about 18- and 9-fold weaker binding for compactin (Kd=84 μM) to CYP109E1 
compared to simvastatin (Kd=4.7 μM) and lovastatin (Kd=9.6 μM), respectively (Table 1 in Chapter 
2.3). Therefore, CYP109E1 is an attractive target for further improvement via mutagenesis. In 
general, active site engineering is an effective strategy to enhance the catalytic activity or especially 
the selectivity of P450s (Wong, 1998). There are few factors that control the selectivity of P450: (i) 
the affinity of a compound to the binding pocket that is determined by hydrophobicity of the molecule 
and the active site architecture, (ii) the reactivity of a particular C-H bond in the molecule determined 
by the bond energy, and (iii) the limitations determined by the active site adapting the ligand relative 
to oxidizing species and hindering its mobility (Ortiz de Montellano, 2010). The change in the 
selectivity of P450 towards its substrate through active site engineering is promising due to the fact 
that it depends mostly on the distance between the oxidation site of the substrate and the ferryl oxygen 
(Wong, 1998). The identification of the key residues involved in the substrate recognition is 
fundamental for successful active site re-design, which can be accomplished by site-directed 
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mutagenesis studies. It is important to note, that mutations in the active site can also have negative 
effects on heme redox potential causing limitation of electron transfer, on oxygen activation and 
proton delivery as well as on productive substrate binding (Makris et al., 2007). On the other hand, 
mutations away from the active site, in the substrate entrance channel or on the protein surface, such 
as the region interacting with redox partners, can improve the activity of a P450. In order to enhance 
the 6′β-hydroxylation activity of CYP109E1 towards compactin, several single alanine mutants, I85A, 
V169A, K187A and E245A, have been tested in vitro (Figure S4a). These mutants were created in 
previous and parallel studies, showing higher catalytic activities for the formation of either 16β-
hydroxytestosterone or 25-hydroxyvitamin D3 (Abdulmughni et al., 2017; Jóźwik et al., 2016). 
Among the screened mutants the I85A variant showed higher selectivity for the formation of 
pravastatin (>99%) and a 2.5-fold increase in catalytic activity in comparison with the wild type 
(Figure S4b). Thus, the position 85 was found to be important for compactin conversion by 
CYP109E1 and was further investigated in B. megaterium using position-85 single mutants 
substituted to several hydrophobic and polar charged residues: I85A, I85V, I85M, I85F, I85W, I85D 
and I85R (kindly provided by Ammar Abdulmughni). As shown in Figure 8a, the valine substitution 
slightly increased the activity, albeit decreased the selectivity. Substitutions by hydrophobic residues 
bigger than isoleucine (methionine, phenylalanine and tryptophan) drastically decreased the activity 
(Figure 8a), whereas substitution by the charged amino acids arginine and aspartic acid completely 
abolished it (data not shown). Similar to in vitro result, substitution of isoleucine with alanine 
significantly increased the activity as well as selectivity compared with the wild type in vivo (Figure 
8b, c and d). The isoleucine residue at position 85 is located in the active site pocket on the BC loop 
(SRS1) near to the heme. This and analogous positions, such as F87 of CYP102A1, have been 
reported to be crucial for determining P450 selectivity towards its substrates and catalytic activity 
(Gricman et al., 2015). For example, the I85A mutant of CYP109E1 improved the selectivity of 
CYP109E1 towards vitamin D3 yielding an about 2-fold increase of 25-hydroxyvitamin D3 
production, whereas the F87A mutant of CYP102A1 enhanced a NADPH-supported hydroxylation 
activity towards p-nitrophenoxydodecanoic acid 2.5 times and an H2O2-supported activity even 
further (Abdulmughni et al., 2017; Li et al., 2001). In contrast to vitamin D3 conversion, the 
replacement of isoleucine 85 with alanine of CYP109E1 increased not only the selectivity but also the 
catalytic activity about 3-fold (Figure 8). Thus, the I85A variant was identified as very promising for 
further optimization. This CYP109E1 single mutant, on the one hand, has the potential to be applied 
for establishing a high-yield pravastatin-producing whole-cell system such as Penicillium 
chrysogenum (McLean et al., 2015). On the other hand, it is also interesting as a basis for further 
improvement of the CYP109E1 activity through mutagenesis. The I85 residue was predicted to 
involve in hydrophobic interactions of CYP109E1 with compactin by molecular docking (Figure 5a in 
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Chapter 2.3). Other putative compactin binding residues identified by docking calculations, L238 
(SRS4), L292 and H293 (SRS5), might be also highly interesting for further investigation.   
 
Figure 8. In vivo conversion of compactin by selected I85 mutants (a). "(-)" selectivity similar or lower than of 
WT, "(+)" selectivity higher than of WT. Comparison of wild type (WT) and I85A in B. megaterium MS941 (b). 
Conversion of WT (solid), of I85A (dashed). The data represents the mean of three independent measurements 
with the corresponding standard deviations. HPLC chromatograms of compactin conversion by WT (c) and 
I85A mutant (d) 
Moreover, it seems promising to re-design CYP109E1 according to the best pravastatin-producing 
mutant of CYP105AS1 from A. orientalis, P450prava, due to the similarity of mutated residues to 
CYP109E1. P450prava is a quintuple mutant of CYP105AS1 with enhanced stereo-selectivity and 21-
fold improved affinity for compactin compared to the wild type (McLean et al., 2015; Yasuda et al., 
2018). The sequence alignment of P450prava (I95T/Q127R/A180V/L236I/A265N) and CYP109E1 
indicated that two mutated residues, arginine at position 127 and valine at position 180, already exist 
in the wild type of CYP109E1 (R117 and V169) (Figure 9). Two residues, I95 and L236, substituted 
with threonine and isoleucine in P450prava, respectively, are present in CYP109E1 in their original 
forms (I85 and L238). Their structural localizations in the active site are also very similar (Figure 10). 
Therefore, substitution of these residues in CYP109E1 with the amino acids similar to P450prava seems 
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to be promising. Furthermore, the fifth mutated residue 265 is distant from the active site and is 
proposed to be important for the activity and/or stability of CYP105AS1 (Yasuda et al., 2018). 
Therefore, it would also be interesting to investigate the corresponding residue in CYP109E1 (residue 
267).  
 
 
Figure 9. Part of the sequence alignment of CYP109E1 and the quintuple mutant of CYP105AS1, P450prava, 
showing the mutated residues (in red). Substitutions of P450prava present also in CYP109E1 are shown in blue. 
The alignment was generated with Clustal Omega (Goujon et al., 2010; Sievers et al., 2011)   
 
 
Figure 10. Structural similarity of the two active site residues of CYP109E1 (magenta) and CYP105AS1 
(purpleblue): I85, I95 (a) and L238, L236 (b). For the alignment substrate-free crystal structures of CYP109E1 
(PDB ID: 5L90) (Jóźwik et al., 2016) and CYP105AS1 (PDB ID: 4OQS) (McLean et al., 2013), and PyMOL 
(DeLano Scientific, CA, USA) were used. The root mean square deviation (RMSD) is 1.29 Å   
 
3.4     Conclusions 
 
Taken together, this work provides novel insights into in vitro and in vivo catalysis of CYP106A2 and 
CYP109E1 enzymes from B. megaterium. The well-studied CYP106A2 was further characterized as a 
highly regio- and stereo-selective 15β-hydroxylase of prednisone and dexamethasone. The newly 
CYP109E1     60 E----------QKNIFSSDRRPPQNQRQTALGTSLINIDPPKHAEMRALVNKAFTPKAMK 
P450prava    61 IDPRFSNRPEHKHPVFSVIPRPGG-ATKAPAPGWFTNMDAPEHTRYRRMLISQFTVRRIK 
                           :: :**   **     ::     : *:* *:*:. * :: . ** : :* 
 
CYP109E1        AWEPKIA ITNELLQEVEH-LEDIDIVEHLSYPLPVMVIADILGVPIEDQRQFKDWSDII R
P450prava       ELEPRIV ITEDHLDAMAKAGPPVDLVQAFALPVPSLVICELLGVSYADHAFFQEQTTIM R
                  **:*.***:: *: : :    :*:*: :: *:* :**.::***   *:  *:: : *: 
 
CYP109E1        AGPSNNERETLEKLQQEKMKANDELETYFYRIIEEKRTRPGDDIISVLLQAKEEGKQLT  V
P450prava       SVD---------KTQDEVTTALGKLTRYIAELVATKRLSPKDDLLGSLIT----DTDLT  V
                *:           * *:*  .* .:*  *: .::  **  * **::. *:     ..:** 
 
CYP109E1        DEEIVGFSILLLIAGNETTTNLISNTIYCLMEDKASFERLKREKELLPSGIEEVLRYRSP 288 
P450prava       DEELTNIALILLVAGHETTANMLGLGTFALLQHPEQIANLD-----SPDAVEELLRYLSI 281 
                ***:..::::**:**:***:*::.   :.*::.  .: .*.      *..:**:*** *  
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identified CYP109E1 was found to act as a versatile statin, norisoprenoid and sterol oxidase 
performing, among others, the industrially important 6′β-hydroxylation of compactin to the drug 
pravastatin. This enzyme has been characterized as one of a few highly stereo-selective compactin 
hydroxylases, showing higher pravastatin yield within 4 h in vivo compared to other wild type P450 
systems. Furthermore, this study has shown the ability of CYP106A2 and CYP109E1 whole-cell 
biocatalysts to produce diverse biotechnologically and pharmaceutically interesting compounds, such 
as drug derivatives (15β-hydroxyprednisone, 15β-hydroxydexamethasone, 6′β-hydroxy-lovastatin, 
3′α-hydroxy-simvastatin and 4″-hydroxy-simvastatin), valuable oxysterols (24(S)-hydroxycholesterol 
and 25-hydroxycholesterol) and several terpenoids (3-hydroxy-α-ionone, 4-hydroxy-β-ionone, 11,12-
epoxy-nootkatone, 4(R)-hydroxy-isolongifolen-9-one, 3-hydroxy-α-damascone, 4-hydroxy-β-
damascone and 3,4-epoxy-β-damascone). The investigated systems were found to be suitable for 
generating these complex organic molecules on milligram-scale. Moreover, they have demonstrated 
unique yet simple ways to produce new compounds, such as 2-hydroxy-β-damascenone, 
15β,17,20β,21-tetrahydroxy-preg-1,4-dien-3,11-dione and 15β,17,20β,21-tetrahydroxy-preg-4-en-
3,11-dione, and, by doing so, make the functional investigation of these substances possible. The 
obtained results provide an important basis for further improvements of CYP106A2 and CYP109E1 
as well as their whole-cell systems towards industrial scale.  
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5. Appendix 
 
      5.1     Supplemental methods 
 
CYP109E1-based system in E. coli and cholesterol conversion: the gene encoding CYP109E1 was 
amplified by PCR and cloned into the pSMF2.1CAA vector (Bleif et al., 2012) via SpeI and KpnI 
restriction sites replacing CYP106A2 with CYP109E1. The resulting vector, pSMF2.1E1AA, was 
cotransformed with the chaperone (GroEL-GroES)-coding plasmid pGro12 (Nishihara et al., 1998) in 
E. coli BL21 cells (Novagen). The control strain was created by cotransforming the backbone 
pSMF2.1 vector (Bleif et al., 2012) with pGro12. E. coli cells were cultured at 37 °C in Luria-Bertani 
(pre-culture) and Terrific Broth (main culture) media supplemented with 100 µg/mL ampicillin and 
50 µg/mL kanamycin. At OD600 of 0.5 1 mM δ-aminolevulinic acid and 4 mg/mL arabinose were 
added. The culture were incubated at 30 °C in a rotary shaker and harvested after 22 h. The in vivo 
conversion was performed similar to B. megaterium cells as described previously (Putkaradze et al., 
2017b). Cholesterol was dissolved in 45% 2-hydroxypropyl-β-cyclodextrin solution. Preparative 
whole-cell conversion of cholesterol was carried out in baffled shake flasks using 600 mL E. coli 
culture. UV/Vis detection of cholesterol and its metabolites via HPLC was performed after cholesterol 
oxidase treatment at 240 nm as described elsewhere (Gerber et al., 2015). The conversion products 
were purified via silica gel chromatography and a mixture of hexane and ethyl acetate (7:3) was used 
as a mobile phase. 
NMR data of 25-OH cholesterol: 
1
H NMR (CDCl3, 500 MHz): 0.66 (s, 3H, H18), 0.91 (d, 3H, J= 
6.6 Hz, H21), 0.98 (s, 3H, H19), 1.19 (s, 6H, H26, H27), 3.51 (m, 1H, H3), 5.33 (m, 1H, H6); 
13
C 
NMR (CDCl3, 125 MHz): 11.85 (C18), 18.67 (C21), 19.31 (C19), 20.75 (C23), 21.06 (C11), 24.27 
(C15), 28.23 (C16), 29.66 (C26, C27), 31.63 (C2), 31.89 (C7, C8), 35.73 (C20), 36.43 (C22), 36.49 
(C10), 37.23 (C1), 39.76 (C12), 42.27 (C4), 42.32 (C13), 44.39 (C24), 50.10 (C9), 56.05 (C17), 56.74 
(C14), 71.16 (C25), 71.81 (C3), 121.71 (C6), 140.74 (C5). 
NMR data of 24(S)-OH cholesterol: 
1
H NMR (CDCl3, 500 MHz): 0.66 (s, 3H, H18), 0.90 (m, 9H, 
H21, H26, H27), 0.98 (s, 3H, H19), 3.29 (m, 1H, H24), 3.51 (m, 1H, H3), 5.33 (m, 1H, H6); 
13
C NMR 
(CDCl3, 125 MHz): 11.85 (C18), 16.67 (C26), 18.80 (C27), 19.05 (C21), 19.38 (C19), 21.06 (C11), 
24.26 (C15), 28.19 (C16), 30.68 (C23), 31.63 (C2), 31.91 (C8), 31.94 (C7),  32.17 (C22), 33.11 
(C25), 35.92 (C20), 36.48 (C10), 37.22 (C1), 39.74 (C12), 42.27 (C4), 42.31 (C13), 50.08 (C9), 55.90 
(C17), 56.71 (C14), 71.80 (C3), 77.42 (C24), 121.70 (C6), 140.73 (C5). 
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5.2     Supplemental data 
 
 
Figure S1. Chemical structures of novel CYP109E1 substrates with hydrocarbon side chain 
 
Figure S2. HPLC chromatograms of biotransformation of cholesterol by CYP109E1: in vitro conversion of 100 
μM substrate (a), in vitro control reaction without CYP109E1 (b), whole-cell conversion of 200 μM substrate 
with E. coli BL21 strain transformed with pSMF2.1E1AA and pGro12 (c), comparison of cholesterol 
conversion with B. megaterium and E. coli cells (d).  
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Figure S3. HPLC chromatograms of in vitro conversion by CYP109E1 of vitamin D2 (a), 7-ketocholesterol (b), 
ergosterol (c) and stigmasterol (d). Conversions were performed using a reconstituted CYP109E1 system as 
described elsewhere (Putkaradze et al., 2017b). Each substrate, dissolved in 45% 2-hydroxypropyl-β-
cyclodextrin solution, was added to a final concentration of 100 μM and the samples were incubated for 1 (7- 
ketocholesterol and ergosterol) or 2 h (vitamin D2 and stigmasterol). Conversion of vitamin D2 was detected at 
265 nm, of ergosterol at 280 nm, other conversions were detected at 240 nm as described elsewhere (Gerber et 
al., 2015)  
 
 
 
 
 
 
 
 
Figure S4. CYP109E1 mutant screening for compactin conversion in vitro (a). Comparison of compactin 
conversion by WT and I85A performed in triplicate (b). "(-)" selectivity lower than of WT, "(+)" selectivity 
higher than of WT 
 
 
